Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants

Nicola S. Klein, Ben F. M. Wijnen, Joran Lokkerbol, Erik Buskens, Hermien J. Elgersma, Gerard D. van Rijsbergen, Christien Slofstra, Johan Ormel, Jack Dekker, Peter J. de Jong, Willem A. Nolen, Aart H. Schene, Steven D. Hollon, Huibert Burger, Claudi L. H. Bockting*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number12
Number of pages9
JournalBjpsych open
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • Depressive disorders
  • antidepressants
  • cognitive behavioural therapies
  • cost-effectiveness
  • economics
  • MAJOR DEPRESSIVE DISORDER
  • RECURRENT DEPRESSION
  • RELAPSE PREVENTION
  • BEHAVIORAL THERAPY
  • FOLLOW-UP
  • HEALTH
  • METAANALYSIS
  • RELAPSE/RECURRENCE
  • INTERVENTIONS
  • PREFERENCE

Cite this

Klein, N. S., Wijnen, B. F. M., Lokkerbol, J., Buskens, E., Elgersma, H. J., van Rijsbergen, G. D., Slofstra, C., Ormel, J., Dekker, J., de Jong, P. J., Nolen, W. A., Schene, A. H., Hollon, S. D., Burger, H., & Bockting, C. L. H. (2019). Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants. Bjpsych open, 5(1), [12]. https://doi.org/10.1192/bjo.2018.81